Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biohaven’s Q3 Nurtec ODT Sales Indicate Gains Across Multiple Launch Parameters

Growth Seen In First Full Quarter With Dual Migraine Indications

Executive Summary

The company pre-announced $136m in third quarter sales, beating analyst consensus and signaling both increased oral CGRP inhibitor market share and improved per-prescription net revenue.

You may also be interested in...



AbbVie Ready To Leverage Migraine Franchise In Crowded Market

The US FDA approved the oral CGRP inhibitor Qulipta (atogepant) for migraine prevention, making AbbVie the only company with three drugs for three different migraine indications.

Biohaven Faces Another Pipeline Upset, But Focus Remains On Migraine Portfolio

The company, which has reported no R&D successes outside of its CGRP inhibitor platform, said verdiperstat did not differentiate from placebo on any endpoints in multiple system atrophy.

With Biohaven's Nurtec ODT Off And Running, Focus Turns To What Is Next

The oral CGRP inhibitor for migraine generated solid second quarter results as the company expanded to the prevention setting. Several new potential growth drivers are moving through the pipeline.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145186

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel